MSstatsPTM: Statistical Relative Quantification of Posttranslational Modifications in Bottom-Up Mass Spectrometry-Based Proteomics

Authors
Devon Kohler, Tsung-Heng Tsai, Erik Verschueren, Ting Huang, Trent Hinkle, Lilian Phu, Meena Choi, and Olga Vitek

Correspondence
choi.meena@gene.com; o.vitek@northeastern.edu

In Brief
MSstatsPTM detects statistical differences between posttranslational modifications and global protein abundances. It includes novel methodology to remove confounding between the effect of individual modification versus the global protein. MSstatsPTM is implemented as an open-source R package available on Bioconductor. The package can be applied to a variety of experimental designs, including those which are label-free and label-based. The package has been benchmarked on several datasets including simulated datasets, a spike-in controlled investigation, and multiple biological experiments.

Highlights
• MSstatsPTM differentiates statistical changes in PTMs and global protein abundances.
• Novel methodology removes confounding between the modification and global protein.
• MSstatsPTM is an open-source R package available on Bioconductor.
• The package is applicable to a variety of experimental designs and labeling methods.
• Benchmarked on simulated data, a spike-in mixture, and biological investigations.

2023, Mol Cell Proteomics 22(1), 100477
© 2022 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
https://doi.org/10.1016/j.mcpro.2022.100477
MSstatsPTM: Statistical Relative Quantification of Posttranslational Modifications in Bottom-Up Mass Spectrometry-Based Proteomics

Devon Kohler, Tsung-Heng Tsai, Erik Verschueren, Ting Huang, Trent Hinkle, Lilian Phu, Meena Choi, and Olga Vitek

Liquid chromatography coupled with bottom-up mass spectrometry (LC-MS/MS)-based proteomics is increasingly used to detect changes in posttranslational modifications (PTMs) in samples from different conditions. Analysis of data from such experiments faces numerous statistical challenges. These include the low abundance of modified proteoforms, the small number of observed peptides that span modification sites, and confounding between changes in the abundance of PTM and the overall changes in the protein abundance. Therefore, statistical approaches for detecting differential PTM abundance must integrate all the available information pertaining to a PTM site and consider all the relevant sources of confounding and variation. In this manuscript, we propose such a statistical framework, which is versatile, accurate, and leads to reproducible results. The framework requires an experimental design, which quantifies, for each sample, both peptides with PTMs and peptides from the same proteins with no modification sites. The proposed framework supports both label-free and tandem mass tag-based LC-MS/MS acquisitions. The statistical methodology separately summarizes the abundances of peptides with and without the modification sites, by fitting separate linear mixed effects models appropriate for the experimental design. Next, model-based inferences regarding the PTM and the protein-level abundances are combined to account for the confounding between these two sources. Evaluations on computer simulations, a spike-in experiment with known ground truth, and three biological experiments with different organisms, modification types, and data acquisition types demonstrate the improved fold change estimation and detection of differential PTM abundance, as compared to currently used approaches. The proposed framework is implemented in the free and open-source R/Bioconductor package MSstatsPTM.

Signaling mechanisms allow cells to mount a fast and dynamic response to a multitude of biomolecular events. Signaling is facilitated by the modification of proteins at specific residues, acting as molecular on/off switches (1–3). Characterizing relative abundance of a modification site’s occupancy repertoire across experimental conditions provides important insights (4). For example, meaningful patterns of changes in posttranslational modifications (PTMs) abundance can serve as biomarkers of a disease (5). Alternatively, distinguishing the quantitative changes in a PTM from the overall changes of the protein abundance helps gain insight into biological and physiological processes operating on a very short timescale (6–8). This helps to distinguish between relative site occupancy changes at steady-state protein levels, typical for short timescale signaling events, and observed relative changes of PTMs as a result of underlying gene expression or protein abundance levels.

Bottom-up liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is a tool of choice for unbiased and large-scale identification and quantification of proteins and their PTMs (9, 10). However, LC-MS-based interrogation of the modified proteome is challenging, for a number of reasons. First, the relatively lower abundance of modified proteoforms dictates that a global interrogation can only be achieved through large-scale enrichment protocols with modification-specific antibodies or beads (11). Variability in the enrichment efficiency inevitably affects the reproducibility of the number of spectral features (e.g., peptide precursor ions or their fragments) and their intensities. Second, contrary to the often large number of identified peptides that can be used to quantify protein abundance, there are relatively few representative peptides that span a modification site, and there may be multiple modified sites on a single peptide (28). Third, unless early signaling events are interrogated, the interpretation of the relative changes in modification occupancy are inherently confounded with changes in the overall protein abundance, complicating the interpretation of the results (6, 12). Finally, technological aspects of bottom-up MS
The framework requires an experimental design, which belies the need for methods not originally designed for this task. Researchers use methods such as t test (13), analysis of variance (ANOVA) (14), or Limma (15), by taking as input the intensity ratios of modified and unmodified peptide summaries and comparing the mean abundance of different PTM sites. Such approaches do not fully account for all the sources of uncertainty. As the result, these approaches are either not directly applicable to experiments with nontrivial designs (such as experiments with multiple conditions, paired and time course designs, and experiments with labeling) or require the analysts to exercise nontrivial statistical expertise. This manuscript proposes a versatile statistical analysis framework that accurately detects relative changes in PTMs. The framework requires an experimental design, which quantifies, for each sample, both the peptides with PTMs and peptides from the same proteins with no modification sites. The framework supports data-dependent acquisitions (DDAs) that are label-free or TMT-based. The statistical methodology separately summarizes the abundances of peptides with and without the modification sites and fits separate linear mixed effects models that reflect the biological and technological aspects of the experimental design. Unmodified peptides may or may not span a modifiable site. Next, model-based inferences regarding the PTM and the unmodified protein-level summaries are combined to account for the confounding between these two sources.

We evaluated the proposed framework on two datasets from computer simulations, one benchmark controlled mixture and three biological investigations. The datasets illustrate a diverse set of organisms, modification types, acquisition methods, and experimental designs, showing the applicability of the framework to a variety of situations. By appropriately leveraging the information from the unmodified portion of the protein sequence, the proposed approach improved the accuracy of the estimates of PTM fold changes and produced a better calibrated false positive (FP) rate of detecting differentially abundant PTMs as compared to existing methods. In particular, accounting for the confounding from unmodified protein abundance allowed us to characterize the true effect of the modification, avoiding the need for more manual and time intensive follow-up investigation.

The proposed approach is implemented as a freely available open source R package MSstatsPTM, as part of the MSstats family of packages (16, 17), and is available on Bioconductor.
presence of and without confounding with the overall changes in protein abundance.

Dataset 3: Spike-In Benchmark—Ubiquitination—Label-Free

Experimental Design—Fig. 1A overviews the experimental design. Four mixtures (i.e., conditions) were created with varying amounts of human lysate, background E. coli lysates, and human spike-in Ub-peptide mixture. Unmodified peptides from human lysate were viewed as the global proteome. Background E. coli lysate were used to equalize total protein levels. Fifty heavy-labeled Ub-remnant diglycyllysine (KGG) motif peptides from 20 human proteins were spiked into the mixed background of the lysates. Quantitative changes in protein and site abundance of these 20 human proteins were the target of the benchmark. In particular, we distinguished the unadjusted changes (i.e., changes in the abundances of the modified peptides) and the protein-level adjusted changes of (i.e., changes in the abundances of the modified peptides relative to the changes in the abundances of the human lysate). The true log-fold changes between the relevant components of the relevant mixtures are summarized in Fig. 1B. Two replicate mixtures were created per condition.

Data Acquisition—A detailed overview of the methods used to acquire this data is available in Supplementary Sec. 1. Each mixture was analyzed with KGG enrichment and without KGG enrichment (i.e., in a global profiling run), with label-free LC-MS/MS. There was a 90.2% overlap of protein identifications between the identified background-modified peptides and proteins quantified in the global profiling run.

Evaluation—We expect the relative abundances of the spike-in peptides to change as in Fig. 1B. The changes in peptide abundances in all the comparisons except Mix 4 versus Mix 1 were distinct from changes in the global proteome abundances and distinct from zero and were viewed as positive controls. In the comparison of Mix4 versus Mix 1, both the modified peptides and the global proteome background changed two-fold, and as the result, the peptides in this comparison were viewed as a negative control. The background E. Coli lysate peptides were not expected to change in abundance in comparison, after accounting for adjustment, and were viewed as additional negative controls. We evaluated the ability of the statistical methods to avoid FPs, as well as their sensitivity in detecting the differentially abundant spike-in peptides and accurately estimate their expected fold change.

Dataset 4: Human—Ubiquitination—1mix-TMT

Experimental Design—Luchetti et al. [20] profiled human epithelial cells engineered to express Ipah7.8 under a dox inducible promoter. Uninfected cells were measured at 0 and 6 h, while cells infected with S. flexneri bacteria were measured at 1, 2, 4, and 6 h increments, resulting in six total conditions. 11 samples were allocated to one TMT mixture in an unbalanced repeated measure design. All conditions had two biological replicates except for the Dox1hr condition, which was allocated one replicate.

Data Acquisition—The search parameters and data acquisition were as described in [20]. The ubiquitinated peptides and the total proteome (i.e., global profiling) were each conducted in a single LC-MS/MS run. There was a 95% overlap between the identified modified peptides and proteins that were quantified in the global profiling run.

Evaluation—We evaluated the ability of the statistical methods to detect changes in the abundance of modified peptides both before and after adjusting for changes in global protein abundance. The six conditions were labeled Dox1hr, Dox2hr, Dox4hr, Dox6hr, NoDox0hr, and NoDox6hr. All conditions were compared with each other,

---

**TABLE 1**

| Experimental type | Dataset | No. of conditions | No. of bio. replicates | No. of mod. peptides | No. of mod. features/site | No. of unmod. features/site | Data availability | Analysis |
|------------------|---------|------------------|-----------------------|---------------------|--------------------------|-----------------------------|------------------|---------|
| Known ground truth | Computer Simulation 1—Label-free | 2/3/4 | 2/3/5/10 | 1000 | 10 | 10 | Github | |
| | Computer Simulation 2—Missing and low features | 2/3/4 | 2/3/5/10 | 1000 | 2 | 10 | Github | |
| | Spike-in benchmark—Ubiquitination—Label-free | 4 | 2 | 12,137 | 1.37 | 10.17 | MSV000088971 RMSV000000669 | |
| Biological experiment | Human—Ubiquitination=n—1mix-TMT | 6 | 2 or 1 | 8848 | 1.21 | 11.01 | MSV000088966 RMSV000000356 | |
| | Mouse—Phosphorylation—2mix-TMT | 6 | 4 or 3 | 26,433 | 1.67 | 11.61 | MSV000085565 RMSV000000357 | |
| | Human—Ubiquitination—Label-free | 6 | 2 | 10,799 | 1.40 | 1.65 | MSV000078977 RMSV000000358 | |

"Dataset" is the dataset code name. "No. of bio. replicates" shows the number of biological replicates per condition. Simulations were generated with different numbers of replicates. The designs of two biological experiments were unbalanced with unequal replicates per condition. "No. of mod. features/site" is the number of features (i.e., peptide ions) used to estimate the abundance of a single modification. "No. of unmod. peptides/protein" is the number of peptide ions without modifications that were used to estimate the global protein abundance. "Data availability" is the ID of the MassIVE.quant repository or the GitHub repository. "Analysis" is the ID of the MassIVE.quant reanalysis container, containing analysis code and modeling results. All the experiments were conducted in data-dependent acquisition (DDA) mode.
resulting in 15 pairwise comparisons. Since the dataset was a biological investigation, the true positive modifications were unknown. *Shigella* ubiquitin ligase IpaH7.8 was shown to function as an inhibitor of the protein Gasdermin D (GSDMD). GSDMD was actively degraded when IpaH7.8 expression was induced by dox treatment in human cells. We expect IpaH7.8 to function as an inhibitor of GSDMD in the global proteome.

**Dataset 5: Mouse—Phosphorylation—2mix-TMT**

*Experimental Design—Maculins et al. (21) studied primary murine macrophages infected with *S. flexneri*. The experiment quantified the abundance of total protein and of phosphorylation in wildtype (WT) and in ATG16L1-deficient (cKO) samples, uninfected and infected with *S. flexneri*. The abundance of total protein and PTMs were quantified at three time points, uninfected, early infection (45–60 min), and late infection (3–3.5 h). Twenty-two biological samples were allocated to two TMT mixtures in an unbalanced repeated measure design, with 11 samples allocated to each mixture. 16 replicates were spread equally between the early and late WT and cKO conditions, resulting in four replicates per condition. Both the uninfected WT and cKO contained three replicates, with mixture one allocating one replicate to uninfected WT and two replicates to uninfected cKO. Conversely, mixture two contained one replicate of uninfected cKO and two uninfected WT.

*Data acquisition—The search parameters and data acquisition were as described in (21). This experiment included a total proteome (*i.e.*, a global profiling run) and a phosphopeptide enrichment run. There was a 90% overlap between the identified modified peptides and proteins that were quantified in the global profiling run.

*Evaluation—We evaluated the ability of the statistical methods to detect changes in the abundance of modified peptides both before and after adjusting for changes in global protein abundance. The six conditions were labeled KO Uninfected, KO Early, KO Late, WT Uninfected, WT Early, and WT Late. Nine total comparisons were made, namely KO Early-WT Early, KO Late-WT Late, KO Uninfected-WT Uninfected, KO Early-KO Uninfected, KO Late-KO Uninfected, WT Early-WT Uninfected, WT Late-WT Uninfected, Infected-Uninfected, and KO-WT. Since the dataset was a biological investigation, the true positive modifications were unknown.

**Dataset 6: Human—Ubiquitination—Label-Free No Global Profiling Run**

*Experimental Design—Cunningham et al. (22) investigated the relationship between USP30 and protein kinase PINK1 and their association with Parkinson’s Disease. The experiment profiled ubiquitination sites and analyzed changes in the modified site abundance. The experiment had four conditions, CCCP, USP30 over expression (USP30 OE), Combo, and Control. Cell lines were used to create two biological replicates per condition. The abundance of modified peptides was quantified with label-free LC-MS/MS.

*Data Acquisition—The search parameters and data acquisition were as described in (22). This experiment did not include a separate global profiling run to quantify unmodified peptides. In addition to low feature counts for unmodified peptides, this led to substantially fewer matches between modified and unmodified peptides. There was a 41.9% overlap between the identified background modified peptides and proteins that were quantified in the global profiling run.

*Evaluation—We evaluated the ability of the statistical methods to detect changes in the abundance of modified peptides both before and after adjusting for changes in global protein abundance. All the conditions were compared with each other in a full pairwise comparison, resulting in six comparisons. Since the dataset is a biological investigation, the true positive modifications were unknown.

*Background*

**Goals of PTM Characterization, Input to Statistical Analyses, and Notation—Consider a label-free LC-MS/MS experiment in the special**
case of a balanced design with \( I \) conditions and \( J \) biological replicates per condition. For simplicity, we assume that the experiment has no technical replicates, such that each biological replicate is represented by a single LC-MS/MS run. Fig. 2 schematically illustrates this data structure for one protein and one PTM site, \( i = 2 \) and \( J = 2 \). For one protein, the PTM site is represented by \( K \) spectral features (i.e., peptide ions, distinguished by their cleavage residues and charge states). The number of modified and unmodified features typically varies across proteins. Some log2 intensities can be outliers, and some spectral features can be missing. The log2 intensity of Feature \( k \) in Replicate \( j \) of Condition \( i \) is denoted by \( y_{ij}^k \). Conversely, the unmodified portion of the protein is represented by \( L \) spectral features, and the log2 intensity of Feature \( l \) from the unmodified portion of the protein in the same run is denoted by \( y_{ij}^l \). The features can be quantified as part of a same mass spectrometry run or in a separate enrichment and global proteome profiling run.

The population quantity of interest is the difference between the log2 abundances of a PTM site in Condition \( i \) and Condition \( i' \), denoted by \( \mu_i^* - \mu_{i'}^* \) respectively. We are interested in testing the null hypothesis

\[
H_0: \Delta_{PTM} = \mu_i^* - \mu_{i'}^* = 0 \quad vs \quad H_a: \Delta_{PTM} = \mu_i^* - \mu_{i'}^* \neq 0
\]

Unfortunately, this population quantity is inherently confounded with the overall changes in protein abundance. To account for this, it is advantageous to consider a different null hypothesis:

\[
H_0: \Delta_{adj} = (\mu_i^* - \mu_i) - (\mu_{i'}^* - \mu_{i'}) = 0 \quad vs \quad H_a: \Delta_{adj} = (\mu_i^* - \mu_i) - (\mu_{i'}^* - \mu_{i'}) \neq 0
\]

where \( \mu_i \) and \( \mu_{i'} \) reflect the overall log2 protein abundances in Condition \( i \) and Condition \( i' \). These quantities are estimated using protein features with and without the modification site.

**Fig. 2.** Schematic representation of one PTM site, in a special case of a label-free experiment with \( I = 2 \) conditions and \( J = 2 \) biological replicates per condition. After a log2 transform, we are interested in estimating the difference between the population-level PTM abundance between condition 1 and condition 2 (i.e., \( \mu_1^* - \mu_2^* \)), relative to the population-level difference of the overall protein abundance (i.e., \( \mu_1 - \mu_2 \)). These quantities are characterized by the observed spectral features (boxes), i.e., peptides of different charge states. The peptides can be fully cleaved (solid lines) or partially cleaved (dashed lines). Unmodified features (blue) in the enriched runs are removed. The log2 intensities of the modified peptides in condition \( i \), run \( j \), and feature \( k \) are denoted by \( y_{ij}^k \). The log2 intensities of feature \( l \) corresponding to the unmodified peptide in condition \( i \) and run \( j \) are denoted by \( y_{ij}^l \). PTM, posttranslational modification.
MSstatsPTM: Statistical Relative Quantification of PTMs

intensities of the modified and unmodified features on the original scale and then considering replicate-wise ratios of the sums and taking the log₂

\[ u_i = \log_2 \left( \sum_{j=1}^{K} 2^{y_{ij}} \right) - \log_2 \left( \sum_{j=1}^{K} 2^{y_{ij}} \right) \]  

(5)

The approach then models these values with the basic ANOVA, which corresponds to

\[ u_i = (\mu_i - \mu) + \epsilon_i, \text{where } \epsilon_i \sim \mathcal{N}(0, \sigma^2), i = 1, \ldots, J \]  

(6)

The model allows us to estimate \( \Delta_{\text{rel}} \) and its standard error. Based on this model, we can test the more relevant null hypothesis in (Equation 2), by comparing the test statistic against the Student distribution with \( df = (J - 1) \) degrees of freedom in balanced designs.

Although effective, the approach is somewhat simplistic. It is not applicable to experimental designs with more complex sources of biological and technological variation, such as experiments with repeated measurements, experiments with multiple batches, or experiments with TMT labeling. Since (Equation 5) performs the adjustment on the replicate level, the experiment must contain a matching number of replicates in both the modified and unmodified runs. Technological artifacts such as missing values further undermine the calculation of \( u_i \) in (Equation 5). Finally, there is no self contained, straightforward implementation of the method, such as in the form of a coding package, and therefore the approach requires a manual implementation.

**Limma**

The estimation of nuisance variation of the two ANOVA models above is often further expanded with Empirical Bayes moderation implemented in Limma (15, 24, 27–30). A typical application of Limma on summarized modified log₂ intensities takes as input \( \hat{y}_{ij} \) obtained as in (Equation 3), and for each PTM fits the linear model in (Equation 4).

A typical application of ratio based Limma takes as input \( u_i \), obtained as in (Equation 5), and for each PTM fits the linear model in (Equation 6). The Limma versions of the models differ from the models in (Equations 4 and 6) in that they specify additional prior distributions for the model parameters. The priors are estimated from the same data by combining the information across all the proteins and all the PTM as described in (27). Testing the null hypothesis is enhanced by combining the PTM and protein-specific estimates of variation with a consensus estimate obtained from the estimated priors. As the result, in experiments with few biological replicates the standard errors are often smaller, and the degrees of freedom are often larger than without moderation (15). Thus, the approach tends to increase the sensitivity of detecting differential abundance.

Since Limma only improves upon the estimation of variation, its limitations are similar to those of ANOVA. In particular, the method is only directly applicable to experiments with at most two variance components and cannot account for all the sources of variation in experiments with either isobaric labeling or complex designs. There is no self contained implementation of the methods to PTMs, requiring manual transformation and application by the user.

**Isobar-PTM**

Isobar-PTM was also proposed for experiments with LC-MS/MS quantitative strategies that employ isobaric labels such as TMT or isobaric tag for relative and absolute quantification (31). Isobar-PTM expresses MS measurements with a linear model and performs adjustment with respect to protein abundance using the difference between log-ratio of modified peptides in two channels and log-ratio of protein level. Unfortunately, this statistical modeling framework is not applicable to either label-free workflows or experiments with complex designs.

**Relative Protein Quantification in MSstats**

MSstats (16) and MSstatsTMT (17) are a family of R/Bioconductor packages for statistical relative quantification of proteins and peptides in global, targeted, and data-independent proteomics. The packages take as input log₂ intensities \( y_{ij} \). For each protein, the log₂ intensities are first summarized into a single value per protein per run \( \hat{y}_i \) using Tukey’s median polish (32). The summaries are then used as input to fit a flexible family of linear mixed-effects models (33–35). The models are fit separately for each protein. The specific model depends on the design of the experiment, labeling type, and data acquisition type as summarized in supplemental Fig. S1. For example, the unmodified protein features in the simple design in Fig. 2 are modeled with one-way ANOVA

\[ \bar{y}_i = \mu_i + \epsilon_i, \text{where } \epsilon_i \sim \mathcal{N}(0, \sigma^2) \]  

(7)

In contrast, a group comparison experiment with multiple TMT mixtures is modeled as

\[ \bar{y}_{eq} = \mu_i + \text{Mixtures}_{eq} + \epsilon_{eq}, \text{where Mixtures}_{eq} \sim \mathcal{N}(0, \sigma_{eq}), \epsilon_{eq} \sim \mathcal{N}(0, \sigma^2) \]  

(8)

Moreover, the model fit for a particular protein depends on the pattern of missing values in that protein. If some of the terms of the model reflecting the experimental design are not estimable, a simpler model is fit for that protein instead.

Parameters of the model are estimated using restricted maximum likelihood (36). The parameters allow us to estimate the pairwise comparison \( \Delta_{\text{protein}} = \hat{y}_i - \hat{y}_j \) and its standard error. Similar to Limma, MSstatsTMT includes an optional Empirical Bayes moderation of the standard error (17), increasing the sensitivity of detecting differential abundance when the number of biological replicates in each condition is small.

MSstats and MSstatsTMT can also be used at the feature or at the modification site level, as opposed to protein level. For example, summarizing the features per PTM site instead of per protein, the approach allows us to test the null hypothesis in (Equation 1).

The MSstats framework has a number of advantages over the methods above. First, unlike ANOVA and Limma, MSstats and MSstatsTMT are applicable to arbitrary complex experimental designs, including designs with multiple sources of variation and unbalanced designs. Second, the approach is applicable to various data acquisition types, including label-free DDA and data-independent acquisition (DIA) and experiments with TMT labeling. Third, the MSstats packages are compatible with various data processing tools such as Skyline, Spectronaut, MaxQuant, Progenesis, Proteome Discoverer, and OpenMS. Finally, the custom MSstats and MSstatsTMT implementation accounts for potential data artifacts is numerically scalable and stable and is available through both command line and a dedicated graphical user interface.

Unfortunately, the MSstats framework focuses on overall protein abundance and as the result tests the null hypothesis in (Equation 1). It does not account for the confounding between the changes in PTM abundance and the overall changes in protein abundance. This manuscript proposes a simple extension to the methodology in MSstats and MSstatsTMT to test the null hypothesis in (Equation 2).
The statistical framework in MSstatsPTM enables sample size calculation for future experiments studying changes in PTM. The procedure has been described in general in (23) and for protein significance analysis specifically in (39). It requires us to specify the desired levels of the following quantities: (a) \( q \), the false discovery rate (FDR) of detecting differential abundance, (b) \( \beta \), the average Type II error rate, (c) \( \Delta_{adj} \), the minimal log2-fold change in adjusted PTM abundance of interest, (d) \( m_0/(m_0 + m_1) \), the fraction of truly differentially modified PTM sites in the comparison, and (e) \( \sigma_{PTM}^2 \) and \( \sigma_{protein}^2 \), the anticipated variances associated with the pairwise comparisons of conditions for the modified and unmodified protein summaries, respectively. Typically, these variances are estimated from an existing experiment, conducted with the same biological material and measurement workflow.

Given the above quantities and assuming a balanced design that allocates the same number of replicates \( J \) to both modified and unmodified profiling runs, the minimal number of replicates \( J \) for each of \( I \) conditions is chosen to bound the variance of the estimated log2-fold change SE\( \Delta_{adj} \):

\[
\text{SE}(\Delta_{adj})^2 = \left[ \frac{2}{J} \left( \sigma_{PTM}^2 + \sigma_{protein}^2 \right) \right] \leq \left( \frac{\Delta_{adj}}{z_{1-\beta} + z_{1-\alpha/2}} \right)^2
\]

where

\[
\alpha = (1-\beta) \cdot \frac{q}{1 + (1-q) \cdot m_0/m_1}
\]

and \( z_{1-\beta} \) and \( z_{1-\alpha/2} \) are the 100(1-\( \beta \))th and the 100(1-\( \alpha/2 \))th percentiles of the standard normal distribution. Solving for \( J \), the number of biological replicates per condition is

\[
J \geq \left( \frac{2\sigma_{PTM}^2 + 2\sigma_{protein}^2}{\Delta_{adj}^2} \right) \left( z_{1-\beta} + z_{1-\alpha/2} \right)^2
\]
The numerator has two sources of variation, reflecting a larger uncertainty in the adjusted calculation. Therefore, the adjustment typically requires a larger sample size to gain the same sensitivity as the unadjusted estimation.

In (Equation 15), we calculated the required sample size; however, in some cases, the statistical power of an experiment may be of interest. In this case, (Equation 13) is still used, however the number of replicates, $J'$, is fixed and false discovery rate, $q$, is solved for.

**Implementation of MSstatsPTM**

The implementation of the open source R package MSstatsPTM is overviewed in Fig. 3. By leveraging the implementations in MSstats and MSstatsTMT, the proposed approach is versatile. It is applicable to a wide variety of experimental designs, including group comparison, paired designs, time course designs, and unbalanced designs. It is applicable to label-free data acquisitions, such as DDA, DIA, SRM, and label-based data acquisitions, such as TMT. It takes as input lists of identified and quantified spectral features for the PTM and for the unmodified portion of the protein, produced by spectral processing tools such as MaxQuant, Progenesis, or Spectronaut. Conversion, summarization and statistical modeling are performed separately for the PTM and for the unmodified portions of the proteins. Steps 4 and 5 leverage the summarization and modeling functions from MSstats and MSstatsTMT. Model-based summaries are combined to adjust the changes in the PTM abundance for changes in abundance of the unmodified portion of the protein. Finally, sample size calculation for future experiments can be performed using the modeling output. DDA, data-dependent acquisitions; DIA, data-independent acquisition; PTM, posttranslational modification; SRM, selected reaction monitoring.

MSstatsPTM takes as input lists of identified and quantified spectral features, produced by spectral processing tools such as MaxQuant, Progenesis, or Spectronaut (Step 3 of Fig. 3). Conversion is performed separately for the runs enriched in modified peptides and separately for the global profiling runs. We require the processing tools to identify the modification site (i.e., the amino acid in the protein sequence where the modification occurred). This will generally include the amino acid abbreviation, plus its number in the protein sequence. For example, a modification on a 70th amino acid in the sequence, serine should be marked as “S70”. Occasionally the outputs of data processing tools only include the peptide sequence with the modified amino acid highlighted, without indicating the location in the protein sequence. For these cases, MSstatsPTM includes functionality for identifying the location,
given the modified peptide sequence and a FASTA file with the entire protein sequence. The converters output the modified spectral features $\gamma'_{jk}$, and the corresponding unmodified features $\gamma_{jk}$ in the format required for summarization.

The next step is PTM/protein summarization using the `dataSummarizationPTM()` function (Step 4 of Fig. 3). Summarization is performed separately for the PTM features and for the features representing the unmodified portion of the protein. When summarizing the PTM, modified peptide features that span the same modification site are summarized together. Peptides that include multiple modifications are not included in the single modification summarization and are grouped separately. The unmodified protein summarization is performed as discussed above for MSstats. When summarizing the unmodified protein features, the package optionally imputes missing values using an Accelerated Failure Time model (40). When summarizing the modified features, missing value imputation is also possible but should be performed with care. PTMs generally exhibit low feature counts and may be missing due to reasons other than low abundance. These issues can violate the assumptions underlying the imputation and lead to numerically unstable results. The outputs of this step are the run-level summaries for the modified $\tilde{y}_{ij}$ and unmodified $\tilde{y}_{ij}$ features.

Separate statistical models are fit to both feature summaries using the `groupComparisonPTM()` function (Step 5 of Fig. 3). MSstats or MSstatsTMT models are leveraged to automatically reflect the experimental design and the data acquisition. If the base model is not applicable for a particular PTM or protein, e.g., due to missing data, a simplified model is fit. The output of the models are the estimates $\hat{\Delta}_{PTM}$ and $\hat{\Delta}_{protein}$, and their standard errors $\hat{SE}(\hat{\Delta}_{adj})$ and $\hat{SE}(\hat{\Delta}_{adj})$.

After modeling, the model for the modified peptides is adjusted for changes in the abundance of the unmodified portion of the protein, using the methods described above. Modification sites which lack corresponding global profiling information cannot be adjusted for changes in protein abundance. In this case, the implementation reverts to testing the null hypothesis in (Equation 1) using the statistical methods seen in MSstats, applied separately to each modified peptide. The final output is the estimate $\hat{\Delta}_{adj}$ and its standard error $\hat{SE}(\hat{\Delta}_{adj})$.

Finally, the statistical models can be used to calculate the required sample size for future PTM experiments using the `designSampleSizePTM()` function (Step 6 of Fig. 3).

In addition to the above functionalities, the implementation includes visualizations for quality control, `dataProcessPlotsPTM()`, and assessment of the quality of model fit, `groupComparisonPlotsPTM()`.

The implementation relies on functionalities from the R packages MSstats (16) and MSstatsTMT (17), which in turn rely on the R packages lme4 (41) and lmerTest (42). MSstatsPTM is available on Bioconductor, http://www.bioconductor.org/packages/release/bioc/html/MSstatsPTM.html, and Github, https://github.com/Vitek-Lab/MSstatsPTM.

### Evaluation

**Evaluation Criteria**—We compared the performance of MSstatsPTM to that of Limma and ANOVA, both before and after adjusting for changes in the unmodified portion of the protein. Since Isobar-PTM is only applicable to experiments with TMT labeling, it could not be applied to the datasets with known ground truth in this manuscript and was therefore excluded from the comparisons.

MSstatsPTM before adjusting for changes in the unmodified portion of the protein corresponds to base MSstats or MSstatsTMT, modeled on the peptide level as described in supplemental Fig. S1, as appropriate for the experimental design. MSstatsPTM with the adjustment described in Statistical Methods in MSstatsPTM was used without imputing missing values and without Empirical Bayes moderation.

Unadjusted ANOVA, i.e., ANOVA before adjusting for changes in the unmodified portion of the protein, was as in (Equation 4). Adjusted ANOVA, i.e., ANOVA with the adjustment was modeled as in (Equation 6). Finally, unadjusted Limma used the same model formula in (Equation 4), while including a moderated variance estimation. Adjusted Limma was modeled in (Equation 6) including moderated variance estimation. All the evaluations were done at the FDR-adjusted $p$-value cutoff of $q = .05$. More details are in Supplementary Sec. 4.

We evaluated MSstatsPTM on simulated and spike-in datasets with known ground truth in terms of true positives (TPs), false negatives (FNs), and false negatives (FNs) differentially abundant PTMs. The TPs were defined as PTMs with changes distinct from the overall changes in abundance of the unmodified portion of the protein. The TNs were defined as PTMs which, after accounting for the changes in the overall protein abundance, were not differentially abundant. Additional summaries were performed including accuracy, recall, and positive predictive value (PPV) empirical false discovery rate (eFDR) as described in (Equation 16).

\[
\text{Accuracy} = \frac{TP + TN}{TP + TN + FP + FN} \quad \text{Recall} = \frac{TP}{TP + FN} \quad (16)
\]

\[
1 - PPV = \frac{FP}{TP + FP} = \text{empirical False Discovery Rate (eFDR)}
\]

For biological experiments with unknown ground truth, we compared the differentially abundant PTMs with and without adjusting for changes in unmodified protein abundance.

**Protein-Level Adjustment Was Required to Control eFDR in Differentially Abundant PTM**

Fig. 4A summarizes the eFDR reported on Computer Simulation one dataset by MSstatsPTM, adjusted ANOVA,
adjusted Limma and base MSstats, unadjusted ANOVA, and unadjusted Limma-free methods. The simulation mimicked a “clean” label-free group comparison experiment, not compromised by issues such as deviations from model assumptions, missing values, and outliers. All the analyses were performed to control the eFDR at most 5%. Yet, even under these favorable circumstances, the models that did not adjust for confounding from changes in overall protein abundance produced an excessive number of FPs. The versions of the models that accounted for the confounding produced error rates that were much better calibrated at the desired level.

In Noisy Simulations, MSstatsPTM More Accurately Detected Differentially Abundant PTM

Fig. 4B summarizes the overall accuracy of methods adjusting for changes in abundance of the unmodified portion of the proteins in Computer Simulation 2. The simulation mimicked a more realistic label-free group comparison experiment, including low counts of modified features and missing values. We evaluated the impact of low versus high noise of the number of biological replicates and of the number of conditions. For low noise, MSstatsPTM outperformed the existing methods across all conditions and number of replicates, with near 100% accuracy when the replicates were high. As the noise increased the accuracy of all the methods decreased, however MSstatsPTM still outperformed the existing methods. The difference was primarily due to two reasons. First, the ratio-based summarization approach used by Limma and ANOVA requires measurements for both the PTM and unmodified protein. In contrast, MSstatsPTM can leverage the information in the PTM or unmodified portion of the protein if one of the two is missing. On average over all simulations, 3.94% of the total unmodified protein run summarizations used by MSstatsPTM were discarded by Limma and ANOVA due to missing PTM data. No PTM run summarizations were discarded due to missing protein data. Second, the robust Turkey Median Polish summarization in MSstatsPTM was more resistant to outliers.

Supplemental Fig. S2 further compares the fold change estimation across all modified peptides. MSstatsPTM showed a tighter distribution of estimated fold changes around the true fold change. Specifically, the interquartile range (IQR) of the estimated fold change for MSstatsPTM was on average 32.5% smaller than Limma and ANOVA’s IQR. While the mean of the estimated fold changes was generally correct for all the methods, the proposed approach correctly estimated the fold change more often across all PTMs.

In the Label-Free Benchmark Experiment, MSstatsPTM Had a Higher Sensitivity

Fig. 5A summarizes the evaluation on the label-free spike-in group comparison experiment, for all the methods, with and without adjusting for changes in abundance of the unmodified portion of the protein. Without adjusting for changes in unmodified protein abundance, all the approaches incorrectly estimated the log2-fold change of the modified spike-in peptides. After adjustment, the estimation was generally in line with the ground truth for all methods; however, MSstatsPTM’s distribution of estimated fold changes was tighter. On average over all comparisons the IQR of the estimates by MSstatsPTM was 32.86% smaller than that by Limma and ANOVA. As seen in the previous section, the robust summarization by MSstatsPTM was particularly useful when the number of features was low. This was also the case in this experiment, with an average of 1.37 features per PTM. Additionally, the ratio-based summarization used by Limma and ANOVA discarded more data than in the simulations. The ratio-based summarization lost 9.63% of the unmodified protein and 1.94% of the PTM run summarizations used by MSstatsPTM. This additional information lead MSstatsPTM to a more accurate fold change estimation and better calibrated variance.

In Two Biological Experiments With TMT Labeling, MSstatsPTM Corrected for Confounding Between Changes in the PTM and Changes in the Unmodified Protein

Fig. 6A summarizes the results of Dataset 4: Human—Ubiquitination—1mix-TMT in terms of number of differentially abundant PTMs before and after adjustment. Adjusting for changes in abundance in the unmodified portion of the protein caused fewer PTMs to be detected as differentially abundant. A question is whether this was due to adjustment in the log2-fold estimation or to an increase in standard errors during the adjustment (Equation 10). To check that, we considered modified peptides for which the adjusted log2-fold change was within 10% of the unadjusted log2-fold change, but which lost statistical significance after the adjustment. In the
In the case of Dataset 4, only one PTM became nondifferentially abundant due to an increase in standard error. In other words, the decrease in differentially abundant PTMs was primarily due to removing the confounding with global protein abundance and not to larger variance estimates.

Cases where true changes in PTMs were masked by changes in abundance in the unmodified portion of the protein were less frequent. One such case is in Fig. 6B. Luchetti et al. (20) showed that GSDMD was actively degraded when IpaH7.8 expression was induced by Dox treatment. Our

![Graph](image-url)
reanalysis confirmed that the GSDMD protein was downregulated when Dox treatments reached the 4 and 6 h marks. Conversely, ubiquitination of GSDMD at site K62 upregulated abundance between the same conditions. This upregulation was originally confounded by the downregulation of unmodified GSDMD and made the modification appear to have little change between no Dox and Dox 4 and 6 h conditions. The proposed approach accounted for this confounding and the

Fig. 5. Dataset 3: Spike-in benchmark—ubiquitination—label-free. A, the distribution of spike-in peptides log₂-fold change estimated by MSstatsPTM, Limma, and ANOVA with and without adjustment. The expected log₂-fold change is highlighted by a red ‘X’. Protein adjustment removed systematic differences from the expected log₂-fold change in all models. B, the statistical results of MSstatsPTM and Limma modeling the mix3-mix2 and mix4-mix2 comparisons before and after adjustment. The solid horizontal line shows the adjusted p-value cutoff of 0.05. The solid vertical line shows log₂-fold change of 0. The dashed vertical line shows the expected log₂-fold change of the spike-in peptides. Before adjustment, the spike-in peptides did not follow the expected log₂-fold change but were more in line with expectation after adjustment.
modification was detected as differentially abundant, with a log2-fold change of 2.79 between the Dox 1 h and Dox 4 h conditions (supplemental Fig. S6). The change in PTM abundance would have been challenging to observe without the proposed approach. Indeed, the modification contradicts the previous research focusing on global profiling of the GSDMD protein (20).

Fig. 7A illustrates a similar result for Dataset 5: Mouse—Phosphorylation—2mix-TMT. Adjusting for changes in abundance in the unmodified portion of the protein caused fewer PTMs to be detected as differentially abundant. As above, we checked whether this change was due to fold change adjustment or an increased standard error. In the case of Dataset 5548 PTMs were not detected as differential abundant due to an
increased standard error. This corresponded to 3.4% of all the PTMs that became nondifferentially abundant.

Fig. 7B shows an opposite case where the protein exhibits a change in abundance while the modification does not. Before adjusting for changes in the unmodified protein, the modification at S178 of protein TTP was shown to be differentially abundant between WT uninfected and WT late, with a log2-fold change of 2.9. However, the unmodified protein was shown to contribute 69.5% of this change, while the modification only accounted for 30.5% after adjustment (supplemental Fig. S7). This caused the modification to lose differential abundance.
In Label-Free Experiment Without a Separate Global Profiling Run, MSstatsPTM Eliminated the Confounding Due to Changes in the Unmodified Protein, Albeit Less Effectively Than in the Presence of a Global Profiling Run

Unlike the other datasets in this manuscript, Dataset 6: Human—Ubiquitination—Label-free had no unmodified global profiling run. Therefore, after peptide identification and quantification, data from unmodified peptides were used separately in place of a global profiling run. This resulted in a sparse coverage of the modified features by the unmodified protein counterparts. Of the 10,799 identified ubiquitination sites, only 4526 had features from unmodified portion of the same protein. A PTM without features from the unmodified portion of the protein could not be adjusted for the confounding. Additionally, the lack of a separate global profiling run resulted in low feature counts and noisier measurements of the unmodified peptides as compared to the other experiments (Table 1).

Fig. 8 shows the number of differentially abundant PTMs before and after adjustment. After adjusting for changes in abundance in the unmodified portion of the protein, the number of differentially abundant PTMs decreased. However, this was mainly due to the lack of a global profiling run. The decrease in differentially modified PTMs was smaller among PTMs with available unmodified protein counterparts. As above, we tested if this drop in differentially abundant PTMs was due to an increase in standard error. Here only 25 PTMs lost differential abundance due to increased standard error.

Noisy PTM Measurements Benefited From Additional Biological Replicates

Sample size calculations and statistical power analyses help evaluate the benefit of additional biological replicates, in particular when measurements are noisy. Since the proposed approach does not have the restriction of the equal number of modified and unmodified global profiling runs, it is also interesting to evaluate the interplay between the number of replicates of each type in presence of differing amounts of noise. In datasets 4 and 5, the variance of the PTMs was higher than that of the unmodified protein summaries, with median values of PTM variance of 0.45 and protein variance of 0.3. In dataset 6, the variance of the PTM and the unmodified protein summaries were comparable, with a median variance of 0.45. The power analysis took as input these median variance values.

Fig. 9 shows that regardless of the relative amount of variation, larger adjusted log₂-fold changes and larger number of replicates enabled larger statistical power. When the variance of PTMs was equal to the variance of global protein profiles, it did not matter whether we increased the number of PTM runs or the number of unmodified protein runs. However, when the variance of the PTM summaries was higher than that of the unmodified protein summaries, allocating more biological replicates to the PTM profiles lead to a more efficient increase of statistical power.

DISCUSSION

We proposed a statistical modeling framework for detecting differentially abundant PTM and its implementation in MSstatsPTM. The proposed approach removes the confounding of changes in PTMs with changes in the unmodified protein summaries and can reveal modifications of interest that are otherwise entirely masked by changes in abundance in the unmodified portion of the protein. This is valuable, because many PTMs are often found nondifferentially abundant prior to the adjustment, and validating them manually to establish false negatives is generally unfeasible.

![Fig. 8. Dataset 6: Human—ubiquitination—label-free no global profiling run, analysis with MSstatsPTM. A, the overlap of differential modified peptides for the PTM model with and without global protein level adjustment across all comparisons, including all measured PTMs. B, The overlap of differential modified peptides with and without global protein level adjustment, including only PTMs for which features from the unmodified portion of the same protein were also available.](image-url)
Our results show that MSstatsPTM is more accurate and more sensitive than the existing approaches. The gain is due to a more efficient use of the data and to a more accurate representation of the systematic and random variations. While the ratio-based approaches of ANOVA and Limma first consider differences within samples, MSstatsPTM first considers the differences between conditions. This enables a greater flexibility in terms of modeling complex designs, accounting for outliers and missing values and planning subsequent experiments.

The implementation of MSstatsPTM is a straightforward extension of MSstats and is therefore applicable to the full breadth of experiment types supported by MSstats. Although demonstrated here on DDA, it is also applicable to DIA, selected reaction monitoring, and parallel reaction monitoring acquisitions. Additionally, the approach can handle...
experiments that use different strategies for modified versus unmodified peptides, e.g., using label-free methods for unmodified peptides and TMT labeling for modified peptides or vice versa.

The proposed approach assumes that all the peptides are correctly mapped to the underlying proteins and PTM sites and that the features are informative of the protein and PTM abundances. However, multiple modification sites per peptide can confound the abundance of each PTM site. Changes in the unmodified peptide (as opposed to the unmodified protein) can also confound changes in PTM abundance. One potential solution is to quantify the abundance of peptides with one modification and use this to adjust the peptide with multiple sites to remove the confounding. However, this method would likely be challenged by scarcity of modified peptide features containing both a single and multiple modification sites. As the result, peptides with multiple modifications are currently beyond the MSstatsPTM scope.

Overall, MSstatsPTM balances accuracy and practicality and enables the analysis of complex experiments in high throughput. Future work is to carry out the inference and testing for not only the relative change of PTM abundance but also the fraction of the protein that is modified at the particular site (site occupancy, or stoichiometry) and attempt to remove the confounding of individual PTMs in peptides with multiple modifications.

DATA AVAILABILITY

The datasets for the six experiments analyzed in this manuscript are available online. The spike-in and biological experiments raw data, processed data, and R code used for analysis are located on MassIVE. The simulated data and code to generate the data are available on Github. Links to the containers are available in Table 1.

SUPPLEMENTARY DATA

This article contains supplemental materials (18, 43, 44).

Acknowledgments—The authors would like to acknowledge and thank Christopher M. Rose for his suggestion about biological studies and insight into interpreting the results.

Funding and additional information—This work was supported in part by NSF DBI-1759736 and Chan-Zuckerberg Essential Open Source Software Award to O. V.

Author contributions—T.-H. T., E. V., M. C., and O. V. conceptualization; D. K., T.-H. T., E. V., T. H., T. H., M. C., and O. V. methodology; T.-H. T., E. V., T. H., and L. P. investigation; D. K., T.-H. T., E. V., T. H., T. H., and M. C. formal analysis; D. K. and T.-H. T software; D. K., T.-H. T., and O. V. writing—original draft.

Conflict of interest—The authors declare no competing interests.

Abbreviations—The abbreviations used are: ANOVA, Analysis of variance; DDA, Data-dependent acquisitions; DIA, Data-independent acquisition; FDR, false discovery rate; GSDMD, Gasdermin D; KGG, Ub-remnant diglycyl-lysine; MS, mass spectrometry; PTM, Posttranslational modifications; PPV, positive predictive value; SRM, Selected reaction monitoring; TMT, Tandem mass tag.

Received August 29, 2022, and in revised form, November 18, 2022
Published, MCPRO Papers in Press, December 8, 2022, https://doi.org/10.1016/j.mcp.2022.100477

REFERENCES

1. Deribe, Y. L., Pawson, T., and Dikic, I. (2010) Post-translational modifications in signal integration. Nat. Struct. Mol. Biol. 17, 666–672
2. Cohen, P. (2000) The regulation of protein function by multisite phosphorylation—a 25 year update. Trends Biochem. Sci. 25, 596–601
3. Bludau, I., Willems, S., Zeng, W. F., Strauss, M. T., Hansen, F. M., Tanzer, M. C., et al. (2022) The structural context of PTMs at a proteome wide scale. PLoS Biol. 20, 5
4. Mann, M., and Jensen, O. (2003) Proteomic analysis of post-translational modifications. Nat. Biotechnol. 21, 255–261
5. Petushkova, N. A., Zgoda, V. G., Pyatnitskii, M. A., Larina, O. V., Teryaeva, N. B., Potapov, A. A., et al. (2017) Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples. PLoS One 12, e0177427
6. Wu, R., Dephoure, N., Haas, W., Hutlin, E. L., Zhai, B., Sowa, M. E., et al. (2011) Correct interpretation of comprehensive phosphorylation dynamics requires normalization by protein expression changes. Mol. Cell Proteomics 10, M110.009654
7. Chandramouli, K., and Qian, P. Y. (2009) Proteomics: Challenges, techniques and possibilities to overcome biological sample complexity. Hum. Genomics Proteomics 1, 1
8. Kim, M. S., Zhong, J., and Pandey, A. (2016) Common errors in mass spectrometry-based analysis of post-translational modifications. Proteomics 16, 700–714
9. Kall, L., and Vitek, O. (2011) Computational mass spectrometry-based proteomics. PLoS Comput. Biol. 7, 12
10. Roepstorff, P. (1997) Mass spectrometry in protein studies from genome to function. Curr. Opin. Biotechnol. 8, 6–13
11. Huang, J., Wang, F., Ye, M., and Zou, H. (2014) Enrichment and separation techniques for large-scale proteomics analysis of the protein post-translational modifications. J. Chromatogr. A 1372, 1–17
12. Olsen, J., and Mann, M. (2013) Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol. Cell Proteomics 12, 3444–3452
13. Kalpic, D., Hufnic, N., and Lovric, M. (2011) Student’s t-Tests. In: International Encyclopedia of Statistical Science, Springer Berlin Heidelberg, Berlin, Heidelberg: 1559–1563
14. Girden, E. R. (1992) ANOVA: Repeated Measures. Sage; Newbury Park, CA: 84
15. Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., et al. (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucl. Acids Res. 43, e47
16. Choi, M., Chang, C. Y., Clough, T., Broudy, D., Killeen, T., MacLean, B., et al. (2014) MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics 30, 2524–2526
17. Huang, T., Choi, M., Tzouros, M., Golling, S., Pandya, N. J., Banfai, B., et al. (2020) MSstatsTMT: statistical detection of differentially abundant proteins in experiments with isobaric labeling and multiple mixtures. Mol. Cell Proteomics 19, 1706–1723
18. Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., and Gygi, S. P. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 24, 1285–1292
MSstatsPTM: Statistical Relative Quantification of PTMs

19. Choi, M., Carver, J., Chiva, C., Tzouros, M., Huang, T., Tsai, T. H., et al. (2023) ISVIEquant: a community resource of quantitative mass spectrometry–based proteomics datasets. Nat. Met. 17, 981–984

20. Luchetti, G., Roncali, J. L., Chavez, R. A., Schubert, A. F., Kofoed, E. M., Reja, R., et al. (2021) Shigella ubiquitin ligase IpaH7.8 targets gaadem D for degradation to prevent pyroptosis and enable infection. Cell Host & Microbe 29, 1521–1530

21. Maculins, T., Verschueren, E., Hinkle, T., Choi, M., Chang, P., Chalouni, C., et al. (2021) Multiplexed proteomics of autophagy-deficient murine macrophages reveals enhanced antimicrobial immunity via the oxidative stress response. eLife 10, e62320

22. Cunningham, C., Baughman, J. M., Phu, L., Tea, J. S., Yu, C., Coons, M., et al. (2015) USP30 and Parkin homeostatically regulate atypical ubiquitin chains on mitochondria. Nat. Cell Biol. 17, 160–169

23. Kutner, M. H., Neter, J., Nachtsheim, C. J., and Li, W. (2004) Applied Linear Statistical Models, 5th ed., McGraw-Hill/Irwin; New York, NY

24. Schwammle, V., Verano-Braga, T., and Roepstorff, P. (2015) Computational and statistical methods for high-throughput analysis of post-translational modifications of proteins. J. Proteomics 129, 3–15

25. Thomas, S. P., Haws, S. A., Borth, L. E., and Denu, J. M. (2020) A practical guide for analysis of histone post-translational modifications by mass spectrometry: best practices and pitfalls. Methods 184, 53–60

26. Mertins, P., Qiao, J. W., Patel, J., Udeshi, N. D., Clauser, K. R., Mani, D. R., et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat. Met. 10, 634–647

27. Smyth, G. K. (2003) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, https://doi.org/10.2202/1544-6115.1027

28. Smyth, G. K. (2005) Limma: linear models for microarray data. In: Gentleman, R., et al., eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Springer New York, New York, NY: 397–420

29. Zhu, Y., Orre, L. M., Zhou Tran, Y., Mermelekas, G., Johansson, H. J., Malyutina, A., et al. (2020) DExGMS: a method for accurate variance estimation in differential protein expression analysis. Mol. Cell Proteomics 19, 1047–1057

30. Chappell, K., Graw, S., Washam, C. L., Storey, A. J., Bolden, C., Peterson, E. C., et al. (2021) PTMViz: a tool for analyzing and visualizing histone post translational modification data. BMC Bioinform. 22, 275

31. Breitwieser, F., and Collinge, J. (2013) IsobarPTM: a software tool for the quantitative analysis of post-translationally modified proteins. J. Proteomics 90, 77–84

32. Tukey, J. W. (1977) Exploratory Data Analysis. Addison-Wesley; Reading, MA

33. McLean, R. A., Sanders, W. L., and Stroup, W. W. (1991) A unified approach to mixed linear models. Am. Statist. 45, 54–64

34. Faraway, J. J. (2006) Extending the Linear Model with R: Generalized Linear, Mixed Effects and Nonparametric Regression Models. CRC Press; New York, NY

35. Bolker, B., Brooks, M. E., Clark, C. J., Geange, S. W., Poulsen, J. R., Stevens, M. H., et al. (2009) Generalized linear mixed models: a practical guide for ecology and evolution. Trends Ecol. Evol. 24, 127–135

36. Kenward, M., and Roger, J. (1997) Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53, 983–997

37. Satterthwaite, F. E. (1946) An approximate distribution of estimates of variance components. Biometrics Bull. 2.6, 110–114

38. Benjamini, Y., and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289–300

39. Oberg, A. L., and Vitek, O. (2009) Statistical design of quantitative mass spectrometry-based proteomic experiments. J. Proteome Res. 8, 2144–2156

40. Wei, L. J. (1992) The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat. Med. 11, 1871–1879

41. Bates, D., Martin, M., Ben, B., and Steve, W. (2015) Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1–48

42. Kuznetsova, A., Brockhoff, P. B., and Christensen, R. H. B. (2017) lmerTest package: tests in linear mixed effects models. J. Stat. Softw. 82, 1–26

43. Kirkpatrick, D. S., Bustos, D. J., Dogan, T., Chan, J., Phu, L., Young, A., et al. (2013) Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proc. Natl. Acad. Sci. U. S. A. 104, 19426–19431

44. Bakalarski, C. E., Elias, J. E., Villén, J., Haas, W., Gerber, S. A., Everley, P. A., et al. (2008) The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. J. Proteome Res. 11, 4756–4765